A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma

Trial Profile

A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Oct 2017

At a glance

  • Drugs Olaratumab (Primary) ; Docetaxel; Gemcitabine
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ANNOUNCE 2
  • Sponsors Eli Lilly
  • Most Recent Events

    • 25 Aug 2017 Planned End Date changed from 1 Aug 2020 to 1 Jul 2020.
    • 25 Aug 2017 Planned primary completion date changed from 1 Mar 2020 to 1 Aug 2019.
    • 10 Aug 2017 Planned number of patients changed from 215 to 310.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top